产品编号 | 产品名称 | 产品规格 | 产品等级 | 产品价格 |
免疫检查点活性蛋白及相关产品CTLA-4,PD-1,IDO1,B7-H4,LAG-3,Tim-3
◆活性免疫检测点蛋白
B7-H4 (human):Fc (human) (rec.) |
CHI-HF-210B7H4 |
B7-H4 (mouse):Fc (mouse) (rec.) |
CHI-MF-110B7H4 |
CTLA-4 (human):Fc (human) (rec.) |
CHI-HF-210A4 |
CTLA-4 (human):Fc (human) (rec.) (non-lytic) |
CHI-HF-220A4 |
CTLA-4 (human):Fc (mouse) (rec.) |
CHI-HF-211A4 |
CTLA-4 (mouse):Fc (mouse) (rec.) |
CHI-MF-110A4 |
CTLA-4 (mouse):Fc (mouse) (rec.) (non-lytic) |
CHI-MF-120A4 |
PD-1 (human):Fc (human) (rec.) |
CHI-HF-210PD1 |
PD-1 (human):Fc (human) (rec.) (non-lytic) |
CHI-HF-220PD1 |
PD-1 (mouse):Fc (mouse) (rec.) |
CHI-MF-110PD1 |
PD-L1/B7-H1 (human):Fc (human) (rec.) |
CHI-HF-210PDL1 |
PD-L1/B7-H1 (human):Fc (human) (rec.) (non-lytic) |
CHI-HF-220PDL1 |
PD-L1/B7-H1 (mouse):Fc (mouse) (rec.) |
CHI-MF-110PDL1 |
PD-L1/B7-H1 (mouse):Fc (mouse) (rec.) (non-lytic) |
CHI-MF-120PDL1 |
PD-L2 (human):Fc (human) (rec.) |
CHI-HF-210PDL2 |
PD-L2 (human):Fc (human) (rec.) (non-lytic) |
CHI-HF-220PDL2 |
PD-L2 (mouse):Fc (mouse) (rec.) |
CHI-MF-110PDL2 |
◆IDO1酶&主要抑制剂
IDO1 (human) Enzyme+Inhibitor Set |
AG-44B-0006 |
IDO1 (human) (rec.) (His) (highly active) |
AG-40B-0161 |
MMG-0358 Potent Triazole IDO1 Inhibitor AG-CR1-3630
IC50值,mIDO1细胞检测是2nM,hIDO1细胞检测是80nM,hIDO1(pH 6.5)酶活检测是330nM,hIDO1(pH7.4)的酶活检测是71nM。体内有活性。
参考文献
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition: U.F. Roehrig, et al.; J. Med. Chem. 55, 5270 (2012)
◆肿瘤免疫治疗的LAG-3
功能性封闭抗体 |
|
LAG-3 (human), mAb (blocking) (17B4) |
AG-20B-0012 |
LAG-3 (human), mAb (blocking) (17B4) (preservative free) |
AG-20B-0012PF |
LAG-3, mAb (blocking) (11E3) |
AG-20B-0011 |
LAG-3, mAb (blocking) (11E3) (preservative free) |
AG-20B-0011PF |
生物活性蛋白 |
|
LAG-3 (human):Fc (human) (rec.) |
AG-40B-0031 |
LAG-3 (mouse):Fc (mouse) (rec.) |
AG-40B-0039 |
◆T-细胞免疫球蛋白和粘蛋白结构域
Tim-3 (human):Fc (human) (rec.) |
CHI-HF-210T3 |
Tim-3 (mouse):Fc (mouse) (rec.) |
CHI-MF-110T3 |
◆CD1d配体抗肿瘤佐剂
α-Galactosylceramide |
Potent NKT Cell stimulator 强有效NKT 激活剂 |
AG-CN2-0013 |
在人类和小鼠NKT细胞里MHC-I蛋白和CD1d分子脂质结合的特异性配体。
参考文献
LIT: Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine: F. Gableh, et al.; J.
Biomed. Sci. 23, 16 (2016)
CD1d配体